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Abstract
Background: Small populations of highly tumorigenic stem-like cells (cancer stem cells; CSCs) can exist within, and uniquely
regenerate cancers including malignant brain tumors (gliomas). Many aspects of glioma CSCs (GSCs), however, have been
characterized in non-physiological settings.
Methods: We found gene expression similarity superiorly defined glioma ‘‘stemness’’, and revealed that GSC similarity
increased with lower tumor grade. Using this method, we examined stemness in human grade IV gliomas (GBM) before and
after dendritic cell (DC) vaccine therapy. This was followed by gene expression, phenotypic and functional analysis of
murine GL26 tumors recovered from nude, wild-type, or DC-vaccinated host brains.
Results: GSC similarity was specifically increased in post-vaccine GBMs, and correlated best to vaccine-altered gene
expression and endogenous anti-tumor T cell activity. GL26 analysis confirmed immune alterations, specific acquisition of
stem cell markers, specifically enhanced sensitivity to anti-stem drug (cyclopamine), and enhanced tumorigenicity in wild-
type hosts, in tumors in proportion to anti-tumor T cell activity. Nevertheless, vaccine-exposed GL26 cells were no more
tumorigenic than parental GL26 in T cell-deficient hosts, though they otherwise appeared similar to GSCs enriched by
chemotherapy. Finally, vaccine-exposed GBM and GL26 exhibited relatively homogeneous expression of genes expressed in
progenitor cells and/or differentiation.
Conclusions: T cell activity represents an inducible physiological process capable of proportionally enriching GSCs in human
and mouse gliomas. Stem-like gliomas enriched by strong T cell activity, however, may differ from other GSCs in that their
stem-like properties may be disassociated from increased tumor malignancy and heterogeneity under specific host immune
conditions.
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Introduction
The cancer stem cell (CSC) hypothesis posits that neoplastic
clones are exclusively maintained by a small fraction of cells with
stem cell properties in many tumors including glioblastoma
multiforme (GBM), the most malignant primary brain tumor
(glioma) [1]. CSCs are rare within GBM, but are classically
enriched by selection of stem markers such as CD133, or by
neurosphere formation [1,2]. Classical glioma CSCs (GSCs)
regenerate both themselves and more differentiated tumor
progeny [3], but GSC differentiation results in decreased
tumorigenicity [4,5,6,7,8,9]. Thus, destruction or differentiation
of CSCs is thought necessary and perhaps sufficient to effectively
treat tumors such as GBM [10].
Key aspects of GBM malignancy, however, are not easily
integrated into the CSC hypothesis. For example, despite their
higher tumorigenicity, CSCs are more prominent in pediatric
brain tumors such as medulloblastoma and ependymoma than in
GBM [1,2]. In this context, medulloblastomas in particular can be
highly malignant, as evidenced by their assignment of WHO grade
IV, but their overall, progression-free, and 5-year survival rates are
comparable to those of ependymoma, and far exceed those of
GBM [11][12][13]. Thus, CSCs are more prominent in brain
tumors with substantially lower malignancy than GBM. In
addition, cytolytic treatments such as irradiation and chemother-
apy that enrich GSCs [14,15], clinically benefit brain tumor
patients [16,17]. This could be due to a primary influence of GSCs
on tumor recurrence, rather than on overall tumor progression,
although GSC-enriching therapies appear to delay recurrences to
some extent as well [16,17]. Moreover, the effectiveness of anti-
CSC therapy in treating CSC-rare tumors has not been
demonstrated, although it may effectively treat tumors with
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exacerbate malignancy within discrete glioma subcategories [19],
implicating modification of stem-associated malignancy by inde-
pendent tumor properties.
Since many aspects of CSCs have been characterized in non-
physiological in vitro or in vivo systems, further resolution of the
relationship of CSCs to tumor malignancy may hinge on
identifying inducible physiological processes that enhance stem-
like properties. As CSCs are enriched by cytolytic therapy, we
examined whether cytolytic T cell activity [20,21] might represent
one such process. We found that T cell activity enhances most
genetic and functional stem-like properties within gliomas, but fails
to unconditionally enhance either tumorigenicity or heterogeneous
gene expression, thereby providing further clarification on the role
of stem-like tumors in glioma malignancy and diversity.
Methods
Patients
All CSMC patients participating in this study provided written
informed consent for gene profiling, vaccination (where appropri-
ate), and all associated analyses prior to surgery. Human
investigations were performed after approval by the Cedars-Sinai
Medical Center institutional review board and in accord with an
assurance filed with and approved by the U.S. Department of
Health and Human Services. Data from non-CSMC patients was
acquired from publications and/or public databases, and was not
linked to personal information or identifiers. Vaccination of the 6
patients whose tumors are included in microarray analyses here
was performed as previously described in the literature under
phase I [22], or phase II [23] tumor lysate/DC trials (vaccine trial
#s 1 and 2, respectively; trial #2 was a phase II continuation of
trial #1, and employed identical manufacturing and monitoring
protocols), or according to an unpublished phase I vaccine trial
(vaccine trial #3), as shown in Table 1.
Trial #s 1 and 3 completed enrollment and treatment prior to
2005, and do not have NCI registry numbers. Design & objectives
of each trial were to assess safety, as well as immunological and
clinical responses, after vaccine administration to: 12 recurrent
and 2 newly diagnosed high-grade glioma patients (10 GBM, 4
anaplastic astrocytoma; trial #1) [22]; 21 recurrent and 11 newly-
diagnosed high-grade glioma patients (all GBM; trial #2) [23];
and 5 recurrent GBM patients (trial #3, unpublished) as detailed
in their respective protocols (included as supporting documents).
Immunological responses and clinical outcomes have already been
reported for phase I and phase II DC/tumor lysate vaccine trials
[22,23].
For DC vaccination trials, patients were administered 3
vaccines, 2 weeks apart, followed in some cases by a third vaccine
6 weeks later, of up to 10
7 autologous tumor lysate-pulsed
dendritic cells (differentiated from monocytes using IL-4 and GM-
CSF) following irradiation therapy as described [22,23]. Informed
consent was obtained from all patients prior to enrollment into
vaccination trials (enrollment 1999–2005). For all trials, the
primary safety endpoint was the number of Grade 3 or 4
toxicities, and was evaluated in all enrolled patients. Primary
efficacy endpoints were time to survival (TTS) and time to tumor
progression (TTP). TTS was evaluated from the date of surgery
immediately preceding vaccination to the date of death or last
contact (if still living). TTP was evaluated from the same initial
surgery date used for TTS, to date of progression on MRI
(approximately 25% increase in tumor volume), provided
progression was verified either histologically or in serial MRI
scans (including routine FLAIR, gadolinium-enhanced, and
perfusion-weighted MRIs). All diagnostic pathology and scans
were subjected to central tumor board review and consensus.
Post-vaccine immune responsiveness was the primary immuno-
logical endpoint. Vaccinated patients were corticosteroid-free
during all blood collections and vaccinations. Each of up to 4
vaccines consisted of 900 mg autologous tumor lysate/10-40610
6
autologous DC. Vaccination started approximately 15 weeks post-
surgery. Serial MRI scans were performed every 2–3 months,
continuously monitored until late-2006. Tumor lysates were
derived from a single surgical tumor resection immediately
preceding vaccination. No effect of sex or any of the major ethnic
groups on safety, immunological, or efficacy endpoints was
detected. All vaccine patients from whom surgically resected
tumor tissue was available before and after vaccination, and that
yielded RNA of sufficiently quality and quantity for microarray
analysis, were analyzed. This comprised 10–20% of all patients
enrolled on any given vaccine trial as summarized above. Primary
immunological endpoints are presented here only for GBM
patients.
RNA isolation and microarray analysis
At the time of resection, tumors were examined by a
neuropathologist and dissected into two portions, one for tissue
diagnosis by histopathology and the other for RNA extraction.
This procedure was done within 15 minutes of surgical resection
while the tissue was kept on ice. The RNA extraction portion was
then snap frozen in liquid nitrogen and stored at 280uC. Most of
the tumor samples were about 0.5 cm in diameter. Total RNA
from tissue was extracted as previously described [24]. Only
samples with sufficient quality and quantity of RNA were further
analyzed. 10 mg of total RNA was used to synthesize double
stranded cDNA using Superscript Choice (Invitrogen, Carlsbad,
California, USA). Biotin-labeled antisense cRNA was synthesized
by in vitro transcription using the ENZO BioArray HighYield kit
(Enzo Diagnostics, Farmingdale, New York, USA). 20 mg cRNA
was chemically fragmented and was hybridized to Affymetrix HG-
U133 Plus 2 (human) and MG-430 Plus 2 (mouse) GeneChip
arrays (Affymetrix, Santa Clara, California, USA). The quality,
yield, and size distribution of total RNA, labeled transcripts, and
fragmented cRNA were estimated by spectrophotometric analysis
at 260 and 280 nm and electrophoresis on RNA 6000 Nano-
LabChips (Agilent Technologies, Palo Alto, California, USA).
Arrays were washed, stained with streptavidin-phycoerythrin, and
scanned to generate image files. Array data was acquired as
MAS5-normalized (intra-sample) values. 1583 human probe-sets
exhibiting significant alteration in GBM tissue after vaccination
(.1.3-fold change post-vaccine relative to pre-vaccine; p,0.05)
were identified using dChip 2006 software (Table S1). Data was
normalized between samples in dChip or GeneSpring software,
Table 1.
Fig. S3
designation Trial #
Total
# pts
Reference
&p t# NCI Registry #
Pr1, Po1 2 34 [23], pt #5 NCT00576537
Pr2, Po2 1 14 [22], pt # 3N A
Pr3, Po3 3 5 NA NA
Pr4, Po4 1 14 [22], pt #6N A
Pr5, Po5 2 34 [23], pt #20 NCT00576537
Pr6, Po6 1 34 [22], pt #14 NA
doi:10.1371/journal.pone.0010974.t001
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1583 probesets.
DC vaccination of mice
Wild-type C57BL/6J mice were vaccinated 3 and 7 days post-
tumor implantation with 10
7 cultured DC2.4 cells that had been
pulsed 2 hr with GL26 cell lysate (150 mg/ml) injected subcuta-
neously on the flank. CTL assay and flow cytometric stainings of
splenocytes and/or excised brain tumors was performed on
selected terminally symptomatic mice, and exhibited consistent
evidence of anti-tumor T cell function or expansion, respectively.
Microarray, Principal Component Analysis, and
Heirarchical Clustering
Vaccine altered gene lists in GL26 were generated in dChip
2006 and included probesets with a significant (. (P,0.05 by one-
tailed T-test and/or ANOVA) .1.5-fold change in GL26 tumors
recovered from nude vs. vaccinated C57BL/6J (probesets, gene
titles, and post-/pre-vaccine expression values available in Tables
S1 and S2). Immune Modulator gene lists include human or
mouse IL-1,IL-1Rs, IL-6, IL-10, IL-23; prostaglandin E synthase;
Ccl5; Stat3; Tlr genes; MIG; MIP-1a, b; MCP1,2,3; CD70;
CD274; MHC-Ia and MHC–II genes; ST3Gal-I, ST3Gal-II; Fas,
FasL; and glucoceramide synthase. Sonic Hedgehog and EGFR
gene lists include genes regulated by either Sonic Hedgehog and/
or EGFR, according to published sources (probesets and gene titles
available in Tables S1 and S2). Progenitor/Differentiation gene
lists were adapted from Superarray.com website (probesets and
gene titles available in Tables S1 and S2). Principal Component
Analysis was performed using GeneSpring GX 7.3, and
Heirarchical Clustering performed in dChip 2006.
Pathway identification
The differentially expressed probe sets were overlaid on a
cellular pathway map in the Ingenuity Pathway Analysis using
resource database Knowledge Base (Winter 04 Release containing
20,000 genes). The resulting networks are represented in table and
graphic format.
Real-time quantitative PCR
Total RNA was extracted from GL26 tumor cells recovered
from 3 nude, 3 C57BL/6J, and 3 DC-vaccinated C57BL/6J
mouse brains using Trizol (Invitrogen). RNA quality was
confirmed by spectrometry and gel electrophoresis. cDNA was
prepared from 2 ug total RNA using random hexamers and oligo
DT (BioRad, Hercules, CA). Serially diluted pooled cDNA was
amplified with specific primers to assess reaction efficiency, and
tumor samples were amplified in triplicate and detected with
SybrGreen. Mouse (m) GLI1 forward 59-ATC TCT CTT TCC
TCC TCC TCC-39, GLI1 reverse 59-CGA GGC TGG CAT
CAG AA-39; mSHH forward 59-GCT CGC CTG GCT GTG
GA-39, reverse 59-CGC CAC GGA GTT CTC TGC TTT-39;
mN-MYC forward 59- GGA TGA TCT GCA AGA ACC CAG-
39, reverse 59- GTC ATC TTC GTC CGG GTA GAA-39;
mEGFR forward 59- AAT CCC AGG ACC AAC TAT GGC
AGC-39, reverse 59- GAG GCA AAC TTC TGT TCC AAT GG-
39; mCD133 forward 59- TCA GAC CTG GAT GGC ATC GG-
39, reverse 59- CGC CAT GGC CTT AAT CTC TTC G-39;
mGFAP forward 59- GCC ACG CTT CTC CTT GTC TCG-39,
reverse 59- GCC CGT GTC TCC TTG AAG CC-39; mGAPDH
forward 59- GGC CTT CCG TGT TCC TAC-39, reverse 59-
TGT CAT CAT ACT TGG CAG GTT-39. Threshold cycle was
calculated relative to an arbitrary internal control according to the
method of Vandesompele [25]. Expression values were normal-
ized relative to simultaneously amplified GAPDH in all samples,
plotted with standard error bars, and differences assessed by
ANOVA.
CTL assays
Target cell killing by native T cells was according to cytotoxicity
detection kit instructions (LDH, Roche Diagnostics GmbH,
Mannheim, Germany). Briefly, splenocyte effector cells from
DC-vaccinated or non-vaccinated GL26-bearing mice were
titrated in assay medium in sterile 96-well tissue culture plates
by serial dilution (100 ml/well). After washing, GL26 cell
suspension (5610
5 cell/ml) was added at 3.3:1, 10:1, and 30:1
effector:target (E:T) ratios in triplicate, with additional wells
prepared for negative, positive, and splenocyte controls followed
by incubation of cells, 37uC, 5% CO2, 90% humidity) for 6 hours.
Thereafter 100 ml/well supernatant was carefully removed and
transferred into corresponding wells of an optically clear 96-well
flat bottom microplate. 100 ml reaction mixture was added to each
well and incubated 25 min, 25uC in dark. Absorbance at 490 or
492 nm was measured using ELISA reader. Cytotoxicity was
calculated as [(splenocytes GL26 cell mix - splenocyte control)-
negative control]/[positive control - negative control] x 100, and
plotted with standard error bars. Identical methods were used to
determine antigen-independent killing sensitivity of GL26,
GL26B6, GL2B6V, GL26Nu tumor cells, except that
5610
5 cell/ml tumor cells were co-incubated with HTB-157.7
cells, a non-adherent H-2K
b-reactive T cell hybridoma, as
effectors at 10:1, 20:1, and 40:1 E:T ratios in triplicate for 12–
15 hours prior to reading absorbance.
Tissue histology, immunofluorescence and flow
cytometry
Serial coronal sections. 16 mm sections of brains of nude
and DC2.4-vaccinated C57BL/6J mice with GL26 tumor were
cut on a cryostat, and mounted to gelatin-coated slides. For H&E
staining & GFP analysis, frozen glioma sections (14 mm) were fixed
with acetone. Endogenous peroxidase activity was eliminated with
0.3% H2O2/PBS before either visualizing GFP fluorescence
without additional staining, or staining with eosin and
counterstain with hematoxylin. Slides were visualizated at 10X
magnification.
Immunofluorescence staining. sections were fixed in 4%
paraformaldehyde and incubated with primary antibodies 1 hr at
room temp: rat anti-CD133/IgG1 (Chemicon International;
USA., 1: 100); rabbit anti-Sox-2/IgG (Chemicon International;
1: 100); rabbit anti-GFAP/IgG (Sigma-Aldrich; 1: 100), and
mouse anti-Nestin Clone Rat 401/IgG1 (Chemicon International;
USA., 1: 100) diluted in 5% normal goat serum, 0.1% Triton-X.
Fluorescein- or Texas red-conjugated anti-rat, anti-rabbit, or anti-
mouse secondary antibody were applied, and images of tumors
from nude and vaccinated mouse brains were obtained from a
Zeiss axiophot epifluorescence microscope (Carl Zeiss
MicroImaging, Inc., Thornwood, NY) at 20X using identical
camera settings.
Flow cytometry. GL26 tumor cells recovered from 3 nude, 3
C57BL/6J, and 3 DC-vaccinated C57BL/6J mouse brains were
stained with the following Ab: Ki67: Clone B56 (BD Pharmingen,
San Jose, CA.) @ 1:25; rabbit anti-rodent GFAP Polyclonal
(Sigma, St. Louis, MO.) @ 1:100; rat anti-mouse Nestin Clone Rat
401 (Chemicon, Temecula, CA.) @ 1:1000; rat anti-mouse
CD133 Clone 13A4 (Chemicon, Temecula, CA.) @ 1:200;
Rabbit anti-rodent SOX-2 Polyclonal (Chemicon, Temecula,
CA.) @ (1:1000); Goat ant-rodent Shh: Polyclonal (R&D Systems,
T Cells in Glioma Stemness
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(R&D Systems, Minneapolis, MN.) @ 1:250. All 1u Abs were
incubated with cells 30 min in 2% heat-inactivated FBS K (FACS
buffer) hr on ice, washed and incubation with appropriate 2u Ab
@ 1:250 in FACS buffer, 30 min on ice. Cells were run on a
FacScan II cytometer with equivalent gain, gates for positive
staining set according to negative (2u Ab only) controls, and
analysis performed with Cell Quest Software (Stanford, CA.)
Drug Sensitivity
Fresh stock solutions of commercially obtained drugs (5 mg/ml
Erlotinib in DMSO; Genentech, S. San Francisco, or 1 mg/
250 ul Cyclopamine in 95% ETOH; Toronto Research Chem-
icals, Inc, ON, Canada) were prepared for each assay. GL26nu,
GL26B6 and GL26B6V cells (recovered as in microarray methods
above) were cultured at 100,000 per well in 1 mL complete RPMI.
Erlotinib or cyclopamine was added at the indicated concentra-
tions to growth medium without serum, and cultured 24 hr. Cell
suspensions were collected and viable cell numbers determined on
a cell counter (Z2 Coulter Corp, Miami, FL.)
Tumor Cell Implantation in Mice
Female C57BL/6 (Jackson Labs) and nude mice (Foxn1;
Harlan, Inc.) were housed in a pathogen–free vivarium and used
on protocols approved by the Cedars-Sinai Medical Center
IACUC according to federal guidelines. The murine (C57BL/6)
GL26 glioma cell line, which is highly tumorigenic in syngeneic
C57BL/6 mice [26,27,28], was obtained with permission from Dr.
Henry Brem (Johns Hopkins, Baltimore, MD). GL26 cells were
cultured in complete RPMI 1640 medium supplemented with
10% heated-inactivated FBS, 10 mM Hepes, 100 U/ml penicillin,
100 ug/ml streptomycin, and 2 mM L-glutamine (Invitrogen
Corp., N.Y., USA). Cultured GL26 glioma cells were harvested
by trypsinization, and 50,000 GL26 tumor cells intracranially
implanted in 2 ml 1% methylcellulose implanted using a
stereotactic rodent frame, with injection 1 mm posterior and
2.5 mm lateral to the junction of the coronal and saggital sutures
(bregma), at a depth of 2 mm. GL26 tumors in C57BL/6J mice
typically ranged from 15–65 mg. Survival (days from tumor
implantation to acquisition of characteristic spectrum of terminal
neurological symptoms) was assessed by 2-tailed Mann-Whitney
log-rank.
Tumor retrieval, cell culture and transfection
Primary mouse brain tumor cultures were established from
GL26 tumor removed at time of euthanasia after acquisition of
terminal neurological symptoms. Tumor tissue was finely minced
using sterile scissors, rinsed with dissection medium, and dispersed
with trypsin-EDTA. Monolayer cells were plated in T75 flasks
(Costar) and culture in DMEM/Ham’s F12 (Invitrogen,) supple-
mented with 10% FBS, L-glutamine, and antibiotics (100 units/ml
penicillin and 100 mg/ml streptomycin). Non-adherent cells were
washed 12-18 hr post-culture, and thereafter as needed. Adherent
cells were grown for 3-8 passages in culture (3–4 passages for
GL26nu-1 & -2; 6 passages for GL26B6-1 & -2; 5-6 passages for
GL26B6V-1 & -2; 8 passages for all others) RNA was extracted
from cells grown to 80% confluence. GL26B6 cells were
transfected with pGFP plasmid (Clonetech) using Lipofectin
reagent (Invitrogen), followed by selection in medium containing
1.7 mg/ml G418. Uniform expression of GFP by GFP-GL26B6
cells was verified by flow cytometry prior to brain implantation.
GL26 derivative lines (parental GL26, GL26nu, GL26B6,
GL26B6V, and GL26B6-GFP) were validated by 100% intracra-
nial tumorigenicity in T cell-deficient hosts at doses of 50,000 cells
or less. DC 2.4 cells were validated by flow cytometry against
MHCII, CD80 and CD86, and by ability to induce anti-tumor T
cell responses by tumor pMHC I tetramer staining (gp100, Trp-2),
and/or CD8 + IFN-c co-staining of effectors.
Statistical Methods
All statistical methods are indicated for specific assays in their
respective figure legends. All in vitro and animal experiments were
repeated at least twice ($3 total repetitions) with similar results.
Results
T cell-exposed GBM and GL26 gliomas up-regulate stem-
like genes and proteins
Because infallible markers of cancer stem cells have not been
described, we first asked whether assessing stem-like properties of
GBM tumors by global gene expression similarity could discern
GSCs from parental GBMs better than a currently available single
marker, CD133. We thus compared the ability of global similarity
to an averaged GSC microarray expression profile, and that of
CD133 expression, to distinguish GSC lines from native tumors in
two separate databases (Fig. S1). Microarray gene expression
profile similarity correlated significantly with CD133 expression in
both databases (Fig. S1A). Nevertheless, microarray profile
similarity effectively distinguished all GSC samples from non-
fractionated GBM (Fig. S1B), whereas CD133 expression failed to
distinguish any GSCs from GBM, indicating relative superiority in
defining CSC lines by microarray profile similarity. Moreover,
secondary GBM and grade 3 gliomas exhibited greater microarray
similarity to GSCs than did de novo GBM (Fig. S1C), whereas
CD133 expression is reportedly more prevalent in de novo GBM
[29]. In fact, microarray data also indicated that CD133
expression was significantly higher in de novo than in either
secondary GBM or in grade 3 gliomas (Fig. S1C), consistent with
previously published findings [1,2]. Nevertheless, this discrepancy
also emphasizes that CD133 expression alone does not accurately
identify all GSCs [29], and may not reflect stemness as defined by
independent means. This also validated the use of microarray
GSC similarity to distinguish stem-like gliomas more faithfully
than CD133 expression (Fig. S1 and legend).
We next generated microarray expression profiles from patients’
GBM acquired before and after therapeutic dendritic cell (DC)
vaccination or before and after standard therapy. We then
determined the relatedness of these profiles to those of previously
published GBM and GSCs [29]. In addition, GL26 glioma cells
were implanted into brains of T cell-deficient (nude), wild-type
syngeneic (C57Bl/6; WT), or DC-vaccinated syngeneic mice, and
recovered by briefly culturing tumors excised from terminally
symptomatic hosts. This recovery yielded GL26nu, GL26B6, and
GL26B6V cells from nude, wild-type, and DC vaccinated-wild-
type, respectively. We then generated microarray expression
profiles from GL26nu, GL26B6, and GL26B6V RNA in parallel
with the human studies.
Principal Component Analysis (PCA) is a decomposition
technique that produces a set of expression patterns, or principal
components. Linear assemblies of these patterns represent the
behavior of all genes in a given sample, characterizing the most
abundant themes recurring in many genes of that sample. To
determine whether DC vaccination preferentially altered genes
distinguishing GSCs from non-stem gliomas, Principal Compo-
nent Analysis (PCA) was performed using vaccine-altered
transcripts (Fig. 1A), Shh and Egfr pathway transcripts (Fig. 1A),
or independent immune-modulating gene transcripts, from human
GBM and mouse GL26 microarray profiles, and the first three
T Cells in Glioma Stemness
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GeneSpring software (Fig. S2A). This analysis revealed unique co-
clustering of post-vaccine but not pre-vaccine GBM to GSCs.
Vaccine-exposed GL26 (GL26B6V) similarly clustered away from
other GL26 sublines on PCA using analogous sets of transcripts
(Fig. 1A). Co-clustering on PCA is an index of relatedness. Hence,
these findings suggest increased relatedness of post-vaccine GBM
to classical GSCs. Such relatedness was further supported by
significantly increased similarity of post-vaccine GBM to GSCs
across all transcripts (Fig. S2C).
It was not possible to directly determine how similarity to post-
vaccine microarray profiles was acquired in GBM samples from
non-vaccinated patients treated at other institutions. Nevertheless,
we observed that endogenous anti-tumor IFN-c responses [23]
were directly correlated with GSC gene expression in our patients’
samples prior to vaccination (Fig. 2A, Fig. S2B). This is consistent
with the possibility that endogenous immune responses enhance
stem-like gene expression. Together with the observation that
GBM similarity to GSCs increases upon vaccination, this suggests
that endogenous and/or vaccine-induced T cell activity are
sufficient to enhance stem-like gene expression in gliomas.
Since non-vaccine therapies can increase stem-like properties in
GBM [14,15], we addressed whether non-specific post-treatment
affects might account for increased stemness after vaccination. We
therefore asked whether GSC gene expression was distinctly
related to vaccine-associated or standard therapy-associated
alterations in GBM gene expression. This was accomplished by
plotting similarity to the GSC microarray profile (Pearson’s
coefficients across all transcripts) versus similarity to either post-
vaccine or post-standard therapy microarray profiles (Pearson’s
coefficients across all transcripts) within 200 independent GBM
samples (Fig. 1B), and generating exponential correlation coeffi-
cients as a measure of their inter-relatedness. This analysis aimed
to discern whether GSC similarity was more related to vaccine-
induced or standard therapy-induced expression profiles globally,
but is not able to discern further details of what specific genes are
involved in any relationships so identified. GSC similarity
correlated significantly with both post-vaccine and post-standard
therapy similarity. This suggested that stem-like gene expression is
related to both vaccine and standard therapies, although perhaps
more significantly to vaccine therapy (Figure 1B). To examine the
basis of the potentially stronger relationship between stem-like and
post-vaccine gene expression, we divided samples further into
weakly and more strongly stem-like subgroups. This subdivision
revealed that weak similarity to the CSC profile correlated equally
with standard therapy- or vaccine-influenced gene expression, but
higher CSC similarity correlated exclusively with the post-vaccine
profile (Figure 1B). This is consistent with the possibility that a
relatively low level of stem-like gene expression may be conferred
onto GBM by either standard or vaccine therapy, but that
vaccination confers a higher level of stem-like gene expression to
these tumors.
To identify oncogenic pathways potentially involved in T cell-
influenced gene expression, we performed Ingenuity Pathway
Analysis (IPA) on vaccine-treated GBM and GL26. IPA is a
software tool that extracts and categorizes multiplexed information
such as gene expression microarray data into groups based on
known functional involvement of individual components (i.e.,
individual genes) as documented in scientific literature. Such
analysis quantifies pathway involvement by calculating the
proportion of genes within a number of defined pathways that
are altered by a given treatment or manipulation. IPA of
transcripts significantly altered after vaccination in GBM patients
and/or in GL26 recovered from DC vaccine-treated mice
revealed that 7 of the top 11 developmental/oncogenic pathways
were up-regulated in common between human GBM and mouse
GL26 (Fig. S3). In this context, Sonic Hedgehog (Shh), a pathway
implicated in glioma CSCs [8,14,30,31,32,33], was particularly
affected by vaccination (Fig. S3). Similarly, 6 of the top 11
pathways were down-regulated in common between GBM and
GL26 after vaccination, with particular prominence of Egf and
Erk/MapK pathway components (Fig. S3). These data suggest
that vaccination consistently up-regulates developmental/onco-
genic pathways such as Shh, while distinct oncogenic pathways
such as Egfr may be consistently down-regulated.
Shh, CD133 and N-myc up-regulation characterize a highly
oncogenic GSC population [1,2,4,8,14,15,34]. We utilized
GL26nu, GL26B6, and GL26B6V sublines to assess the influence
of absent, weak, and strong anti-tumor T cell activity, respectively,
on these genes, and verified up-regulation of Shh, N-myc, and
CD133 in GL26B6V relative to GL26nu by quantitative PCR
(qPCR; Fig. 2B and legend). In contrast, Egfr and Gfap expression
were significantly decreased in GL26B6V relative to GL26nu.
Moreover, GL26B6 exhibited more modest regulation of these
same genes, in the same direction as GL26B6V (Fig. 2B). Since
non-vaccinated wild-type mice exhibited weak endogenous anti-
tumor T cell activity by CTL assay, and such activity was
substantially increased upon vaccination (Fig. 2C), this suggested
that stem-like gene expression in gliomas is modulated in direct
proportion to anti-tumor CTL activity levels.
Flow cytometry verified increased expression of Shh protein, as
well as of Ki67, a proliferative marker associated with CSC
malignancy [35], as well as decreased expression of Gfap protein
in GL26B6V relative to GL26nu. Incremental modulation of these
proteins was also observed in GL26B6 (Fig. 3A). Immunohisto-
chemical analysis verified that GL26 brain tumors in situ were
Figure 1. Expression microarray profiles of human GBM and mouse glioma. (A) Principal Component Analyses focused on discrete gene
lists were plotted in GeneSpring GX 7.3, and group clusters circled, on: 59 GBMs from UCLA database (‘‘UCLA GBM’’; GEO accession #GSE4412), 12
GBMs from 6 patients collected before and after DC vaccination (‘‘vaccinated GBM’’; GEO accession #GSE9166); 10 GBMs from 5 patients collected
before and after standard radiation and/or chemotherapy (‘‘control GBM’’; GEO accession #GSE9166) (red); CD133
- and CD133
+ CSCs from 6
University of Regensberg GBM patients [29] (‘‘UR GSC’’; GEO accession #GDS2728) (green); stem cell media-cultured GBM lines from 2 Henry Ford
Hospital patients (‘‘HFH CS lines’’; GEO accession #GSE4536); murine GL26 glioma samples recovered and cultured #8 passages from brains of 5
nude (GL26nu), 4 C57BL/6J (GL26B6) and 4 C57BL/6J mice vaccinated with 10
7 tumor lysate-pulsed DC2.4 cells 3 and 7d post -tumor implantation
(GL26B6V; GEO accession #GSE9166). Post-vaccine GBM uniquely exhibited co-clustering with UCLA glioma progenitors within vaccine altered genes
(top row), and similarly constrained expression of SHH and EGFR pathway genes (middle row). Glioma progenitors also exhibited constrained
immune modulator gene expression (Fig. S1A). GL26B6V exhibited parallel trends in all analogous gene lists (right column). (B) Primary GBM
microarray expression values from 200 Henry Ford Hospital patients (GEO accession #GSE4536) were assessed for similarity to averaged expression
values of 6 UCLA glioma CSCs by determining Pearson’s coefficients across 54,674 transcripts, and arranged in order of ascending coefficient values.
Pearson’s coefficients for similarity to the post-vaccine expression profile across all transcripts (averaged from 6 GBM patient samples) were
determined, plotted against the first set of coefficients for each patient, and correlation between CSC and vaccine-induced expression profiles
calculated using exponential trendlines. This analysis was repeated after subdivision of GBM patients into low (black) and high (red) CSC similarity
according to median of relevant Pearson’s coefficients (bottom panels).
doi:10.1371/journal.pone.0010974.g001
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PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e10974Figure 2. Regulation of stem-like gene expression in proportion to anti-tumor T cell activity. (A) CSC similarity (Pearson’s coefficient for
similarity to GSCs – GEO accession #GDS2728 - across all transcripts) from 200 Henry Ford Hospital GBM patients (GEO accession #GSE4536) and 6
CSMC GBM patients was assessed and found to be statistically identical, demonstrating absence of relevant bias in CSMC patients (left panel). Division
of CSMC patients according to median pre-vaccine anti-tumor response levels as described [23] revealed significantly lower GSC similarity in low anti-
tumor responders (0.8460.01 vs. 0.8160.01; P,0.05, one-tailed T-test; n=3 per group), and this levels was also significantly lower than average of
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+ and Gfap
2 in vaccinated WT but not in nude mice
(Fig. 3B). Nestin and Sox-2, additional stem cell proteins, were also
up-regulated on in situ tumors in vaccinated WT mice (Fig. 3B).
Expression of Sox-2, however, was atypical in that it was not
confined to the nucleus (Fig 3B, Sox-2 right panel, top left inset),
although staining of contralateral ventricular cells with the same
antibody revealed predominantly nuclear Sox-2 expression (Fig 3B,
Sox-2 right panel, top right inset). Thus, vaccine-exposed GL26
may retain Sox-2 in the cytoplasm and/or fail to efficiently
transport it to the nucleus, which may limit Sox-2 transcriptional
activity in these cells.
T cell-exposed GL26 gliomas exhibit enhanced
cyclopamine sensitivity, chemoresistance, and
tumorigenesis
The above data suggest that exposure to anti-tumor T cell
activity, induced endogenously or through DC vaccination,
renders gene expression more stem-like in gliomas. To determine
whether exposure to anti-tumor T cell activity mediates stem-like
functional properties, we took advantage of recent evidence
suggesting that stem-like glioma cells are depleted by the Shh
antagonist, cyclopamine [33]. We thus treated GL26nu and
GL26B6V cells (unexposed or exposed to strong anti-tumor T cell
activity, respectively) with cyclopamine, and with Tarceva
(Erlotinib), an inhibitor of Egfr signaling used here as a control.
Cultured GL26B6V cells grew with Tarceva treatment but were
depleted by cyclopamine treatment (Fig. 3C), suggesting relative
resistance to Egfr and sensitivity to Shh inhibition. In contrast,
GL26nu were unaffected by cyclopamine but were depleted by
Tarceva treatment (Fig. 3C), suggesting relative resistance to Shh
and sensitivity to Egfr inhibition. These data suggest that exposure
to anti-tumor T cell activity renders glioma growth increasingly
sensitive to Shh inhibition, and less sensitive to Egfr inhibition.
Previous reports also indicate that GSCs are chemoresistant.
Viability of GL26nu and GL26B6V was examined with and
without temozolamide (TMZ), a standard GBM chemotherapeutic
to which classical GSCs are resistant, to assess whether exposure to
anti-tumor T cells activity induces stem-like drug resistance. TMZ
depleted both GL26nu and GL26B6V in a dose-dependent
manner in vitro, but GL26B6V was far less sensitive than GL26nu
(Fig. 4A). BL26B6 exhibited intermediate TMZ depletion (Fig.
S4A). Together, these results suggest that exposure to anti-tumor
T cell activity proportionally increases glioma chemoresistance in
vitro. In addition, TMZ extended survival of nude mice implanted
with parental GL26, but not of those implanted with GL26B6V
(Fig. 4B), suggesting that exposure to strong anti-tumor T cell
activity increases glioma chemoresistance in vivo. Thus, vaccine-
exposed GL26, like classical glioma stem cells, appear sensitive to
cyclopamine as well as chemoresistant.
We next examined tumorigenicity of vaccine-exposed GL26, as
enhanced tumorigenicity is a consistently reported property of
GSCs. Limiting doses of GL26B6V cells were rapidly lethal in
wild-type mice, whereas the same dose of GL26B6 was less
tumorigenic, and parental GL26 were non-tumorigenic (Fig. 4C).
Thus, prior exposure of gliomas to increasing levels of T cell
activity proportionally enhanced their tumorigenicity upon re-
implantation into immunocompetent hosts. By contrast, implan-
tation of limiting doses of parental GL26, GL26B6, and GL26B6V
did not reveal distinct tumorigenicity in T cell-deficient (nude)
hosts (Fig. 4C; Fig. S4B), as expected of classical GSCs
[1,2,8,33,36,37]. These findings raised the possibility that
vaccine-enriched glioma cells might be somewhat distinct from
classical GSCs enriched by chemotherapy or neurosphere culture.
Underscoring this possibility, DC vaccination enhanced the
survival of GL26 hosts to a greater extent than TMZ (Fig. 4D),
To help clarify the relationship between vaccine-enriched
glioma cells and classical GSCs, we sought to determine whether
treatment with DC vaccine or with TMZ, a chemotherapeutic that
enriches classical GSCs (Fig. 4D) [15], enriched the same stem-like
glioma population. We reasoned that the 2 therapies should
synergize only if they eliminated or otherwise acted on distinct
tumor subpopulations. GL26 was therefore implanted simulta-
neously into WT and nude mice, followed by TMZ treatment
and/or DC-vaccination (WT only). TMZ significantly enhanced
survival in both nude and WT hosts, with maximal enhancement
in unvaccinated WT, but did not synergize with vaccination
(Fig. 4D). This pattern of synergy is consistent with a scenario in
which vaccine-induced T cell activity acts on the same tumor
subpopulation targeted by TMZ chemotherapy, but in which
endogenous T cell activity acts on tumor cells that survive or are
unchanged by chemotherapy.
The above survival study also indicated that host survival is
prolonged by DC vaccination, despite its promotion of tumor cells
with enhanced tumorigenicity in immunocompetent hosts
(Fig. 4C). This may occur because vaccination eliminates a larger
or more malignant non-stem tumor subpopulation than the stem-
like tumor cells it spares. If true, this would implicate selection
rather than induction as a mechanism for T cell-mediated
enrichment of GSCs, as outlined in Fig. 5A. A prerequisite for
such immune-mediated selection is relative resistance of stem-like
tumor cells to T cell killing. In this context, killing of GL26B6V by
the allo-reactive T cell hybridoma, HTB-157.7 [38][39][40][41]
was partially diminished at high effector:target (E:T) ratios relative
to both parental GL26 and to GL26nu (Fig. 5B). Although further
studies are necessary to determine whether such CTL resistance is
sufficient to account for T cell-mediated enrichment of GL26B6V,
its relative resistance to T cell killing is consistent with immune-
mediated selection.
Genetic heterogeneity in T cell-exposed GBM and GL26
gliomas
It has been suggested that, by promoting tumor cell differentiation,
GSCs may enhance genetic heterogeneity within GBM (1). If true,
increasingly stem-like tumors should exhibit increased heterogeneity,
particularly within genes involved in progenitor cell function and/or
differentiation. To test this, we stratified 200 GBM samples into 10
subgroups based on increasingGSC similarity. Wethen assessed pair-
HFH patients (P,0.04; one-tailed T-test). (B) Quantitative PCR was performed using primers to the indicated genes, and products quantified by
SybrGreen on an iCycler system (BioRad, Hercules, CA). RNA was derived from 3 independent low-passage sublines per strain (3–5 passages after
brain recovery). Asterisks denote significant difference in GAPDH-normalized expression of each of the indicated genes in WT or WT, vac-recovered
relative to nude-recovered GL26 cells by ANOVA. Gli1 expression was also marginally but significantly increased in GL26B6V relative to GL26nu (not
shown; 18.9% relative to GAPDH; P,0.002; two-tailed T-test). All reactions were performed in triplicate for each individual tumor subline (3 sublines
per host type). (C) CTL responses of immunocompetent and vaccinated GL26-bearing mice. CTL activity of splenocytes from glioma hosts. CTL activity
of ex vivo-stimulated splenocytes (7 days) from non-vaccinated and vaccinated symptomatic, intracranial GL26-bearing mice against cultured GL26
cells was assessed by tetrazolium assay, and plotted as GL26 lysis–spontaneous (effector + responder)lysis/total lysis. Raw values at higher E:T ratios
were significantly higher those of the lowest E:T ratio in non-vaccinated controls (P,0.02 for 10:1, P,0.003 for 33:1 E:T ratios, respectively; ANOVA).
doi:10.1371/journal.pone.0010974.g002
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PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e10974Figure 3. Stem-like protein expression and function modulated by T cell activity. (A) Flow cytometric staining and analysis was
performed on GL26 tumor section from brains of nude (GL26nu), C57BL6J (WT; not shown), and C57BL/6J mice vaccinated with 2610
6 GL26 lysate-
pulsed DC2.4 cells 3 and 7 days post-tumor implantation (‘‘WT, vac’’). Percentage of positive cells appears above gating bar. Markers shown had
significantly different (P,0.05) positive cell percentages in 3 independent samples of GL26nu and GL26B6V cells by ANOVA and/or one-tailed T-test.
(B) Immunofluorescence staining was performed on GL26 tumor section from brains of nude, and C57BL/6J mice vaccinated with 2610
6 GL26
lysate-pulsed DC2.4 cells 3 and 7 days post-tumor implantation (‘‘WT, vac’’). Results are representative of $ samples/group, with the exception of
CD133, which revealed strongly positive tumor staining in 2 of 4 brains. WT brains generally exhibited staining similar to nude, or intermediate
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(Pearson’s correlation coefficients for every possible sample pair
within each stratified group, considering all probesets) as well as
within genes expressed in cell progenitors or during differentiation
(progenitor/differentiation genes; Pearson’s correlation coefficients
for every possible sample pair within each stratified group,
considering only thos probesets known to be expressed in cell
progenitors or during differentiation). The aim of this analysis was to
determine the degree of gene expression heterogeneity potentially
related to differentiation, between GBMs from different patients as a
function of their stemness.(Fig. 6A). Intriguingly, increasing GSC
similarity did not consistently increase intra-group similarity across all
transcripts, and was even associated with progressively decreased
intra-group similarity (increased heterogeneity) within progenitor/
differentiation genes (Fig. 6A; group GSC-A). Thus, heterogeneous
expression was selectivelyincreased within genes potentiallyrelated to
differentiation, and in direct relation to stemness. This helps validate
the notion that possession of a stem-like tumor genetic profile
enhances GBM genetic heterogeneity in situ.
In contrast, 23 GBM cell lines grown in stem cell media and
stratified into 5 subgroups based on increasing GSC similarity
exhibited uniformly high intra-group similarity (i.e., relative
homogeneity) across all transcripts and within progenitor/
differentiation genes (Fig. 6A). These data demonstrate that
stem-like GBM lines exhibit evidence of homogenized gene
expression, whereas stem-like GBM tumor tissue exhibits hetero-
geneity within progenitor/differentiation genes. Such heterogene-
ity could be ascribed to contaminating non-stem subpopulations
and/or transitional cell states accompanying stem-like GBM in situ
that are subsequently lost in culture. Alternatively, it could be due
to enrichment of distinct categories of stem-like tumor cells by
different environmental constraints.
Because stem-like gene expression in GBM was related to
endogenous rather than vaccine-induced anti-tumor immunity, it
was unclear how vaccine exposure would affect GBM heteroge-
neity within progenitor/differentiation genes. We thus examined
heterogeneity among pre- and post-treatment (vaccine or standard
therapy) GBM pairs from the same patients. Surprisingly, the
relatively high heterogeneity within progenitor/differentiation
genes observed in non- or pre-vaccinated GBM was eliminated
in tumors acquired from the same patients after DC vaccination
(Fig. 6B). Thus, regardless of the specific etiology of this
heterogeneity or its role in GBM phenotypic variation, GBMs
acquired more homogeneous gene expression after exposure to
strong anti-tumor T cell activity.
Whereas these results suggest that strong anti-tumor immune
activity has the ability to homogenize expression of genes
potentially involved in progenitor cell function and/or differenti-
ation, it was still unclear whether the absence of T cell activity
promote heterogeneity within these genes. In this context, the pre-
vaccine heterogeneity observed in GBM patients could have
originated from distinct genetic origins of tumors in different
patients, rather than from the absence of T cell activity per se. To
further clarify the potential impact of anti-tumor T cell activity on
glioma genetic heterogeneity, and to formally address whether the
lack of anti-tumor T cell activity can enhance heterogeneous gene
expression in glioma, we assessed microarray profile similarity
among biological replicates of GL26nu, GL26B6, and GL26B6V
(all dervived from the same parental tumor). Remarkably,
relatively high heterogeneity within progenitor/differentiation
genes was observed only in GL26nu (Fig. 6B). In contrast,
GL26B6 and GL26B6V exhibited more homogeneous gene
expression within progenitor/differentiation genes (Fig. 6B).
Together, these findings suggest that strong anti-tumor T cell
activity is sufficient to render gliomas more stem-like and to
homogenize progenitor/differentiation gene expression. Similarly,
the absence of anti-tumor T cell activity can enhance heteroge-
neous expression within the same set of genes in gliomas.
Discussion
Microarray analyses (PCA and IPA) on all transcripts, vaccine-
altered, and immune-related genes, suggested that in vivo vaccine
treatment rendered GBM gene expression more similar to that of
classical GSCs (Fig. 1, Fig. S2). We considered the possibility that
these results may be dependent on the use of a tumor lysate-pulsed
DC vaccine strategy to elicit anti-tumor CTL activity. In this context,
however, endogenous anti-tumor T cell activity measured prior to
vaccination [23], correlated directly with GBM stemness (Fig. S2B),
suggesting that increased T cell activity in general (endogenous or DC
vaccine-induced), correlated with a stem-like gene expression profile
in these patients. Nevertheless, it is recognized that specific targeting
of GSC antigens during T cell induction may yield distinct findings.
For example, others have previously shown that DCs loaded with
stem-like, as opposed to parental, glioma cells are better able to elicit
an effective immune response against either parental or stem-like
gliomas in mice [42][43]. Such treatment would not necessarily be
expected to increase stem-like properties in surviving tumors,
particularly if T cell activity enriches glioma stemness solely through
selective killing of targeted tumor cells. This raises the possibility that
our own vaccination strategy enriched GSCs because it failed to
include T cell epitopes of GSCs. However, we and others have
observed that anti-tumor T cellsinDC-vaccinated human and mouse
glioma hosts predominantly recognize Trp-2, or dopachrome
tautamerase (DCT; [44][27]), which has been shown to enhancee
stem-like properties in neural progenitors [45]. The molecular
mechansism whereby T cell activity enhances GSC properties in
GBM is therefore unclear, and requires further study to clarify
whether it proceeds via selective destruction of tumor cells and/or by
independent means.
Stem-like properties were assessed in the transplantable murine
glioma, GL26 to determine if T cell activity directly caused an
increase in glioma stemness. GL26 exhibited more stem-like gene
and protein expression (Figs. 1A; 2B; 3A, B; Fig. S2A), as well as
GSC functions including cyclopamine sensitivity (Fig. 3C),
chemoresistance (Fig. 4A, B), and enhanced tumorigenesis in
wild-type hosts (Fig. 4C), after exposure to anti-tumor CTL
activity derived from either endogenous or vaccine-induced T cell
responses. Specifically, GSC-like gene expression, protein expres-
sion, chemoresistance, and tumorigenesis and functional proper-
staining between that of nude and WT, vac (not shown). Marker expression of WT, vac (Prominin
+, GFAP
-, Sox-2
+, Nestin
+) is characteristic of cancer
stem cells. However, Sox-2 expression was not isolated to nuclei in WT, vac GL26 (right panel, top left inset), though Sox-2 staining of contralateral
ventricular cells in the same brain was (right panel, top right inset). (C) Cell numbers in absence or presence of the indicated concentrations of
Erlotinib (Tarceva) or Cyclopamine were determined for low-passage (#5) GL26nu and GL26B6V by Coulter counter. Differences between GL26nu
and GL26B6V for either drug, and between erlotinib and cyclopamine within the same recovered tumor lines were significant (P,0.03 by one-tailed
T-Test and ANOVA), at concentrations above 4 uM. Distinct glioma lines exhibited opposite patterns of drug sensitivity: GL26nu cells were sensitive to
erlotinib but not to cyclopamine, and GL26B6V cells were sensitive to cyclopamine but not to erlotinib, consistent with their reciprocal expression of
EGFR and SHH target genes.
doi:10.1371/journal.pone.0010974.g003
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PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e10974Figure 4. In Vitro and in vivo drug resistance of vaccine treated vs. non-treated tumor cells. A) Cell numbers 6 indicated concentrations of
temozolamide were determined for low-passage (#5) GL26nu and GL26B6V with a Coulter counter. Cell numbers were significantly different (P.0.7;
one-tailed T-test) between GL26nu and GL26B6V at all drug concentrations, and trends were significantly different among 3 independent sublines of
these tumors. (B) Female nude mice (Harlan, Inc.) were injected intracranially with 50,000 GL26 tumor cells, or 50,000 GL26B6V tumor cells, treated by
i.v. injection 7, 8, & 9 days post-tumor implantation with 10 mg/kg temozolamide (TMZ) in 1% DMSO, and days to survival assessed by log-rank. GL26-
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exposed to low but measurable endogenous anti-tumor CTL
activity (GL26B6), and such properties were more dramatically
increased in GL26 exposed to higher DC vaccine-induced anti-
tumor CTL (GL26B6V; Fig. 2B; 3A; 4C; Fig. S4A, B). Together,
these data indicate a strong correlation between anti-tumor T cell
activity and stem-like properties in clinical glioma specimens. In
addition, the observation that T cell presence caused stem-like
properties to increase in GL26 in direct proportion to the level of
anti-tumor CTL activity against this glioma, suggests that stem-like
properties may be directly enhanced by anti-tumor T cell activity.
As such, these data represent the first evidence that tumor
stemness may be regulated by inducible physiological processes
generally, and anti-tumor CTL activity in particular. Nevertheless,
further investigation is required to elucidate the precise nature and
involvement of anti-tumor T cell activity in enhanced stem-like
properties in gliomas.
Shh and EGFR signaling pathways, each of which can mediate
brain tumor generation and/or malignancy, were identified as the
most prominently up- and down- regulated oncogenic pathways,
respectively, common to GBM and GL26 exposed to T cells in vivo.
( F i g .S 3 ) .F u r t h e r m o r e ,s e n s i t i v i ty to cyclopamine a Shh signaling
antagonist, (Fig. 3C), in vitro and in vivo chemoresistance, and resistance
to CTL killing were also enhanced in vaccine-exposed GL26
(GL26B6V; Fig. 4A, B, Fig. 5B). These data suggest that vaccine-
exposed gliomas may be generally resistant to chemical and immune
cytotoxicity, but maintain sensitivity to anti-stem agents including
cyclopamine. It is therefore tempting to speculate that anti-stem agents
might be particularly useful in combination with vaccination to treat
malignant gliomas. It is equally intriguing to speculate that a switch in
dependency from EGFR-mediated to Shh-mediated growth might
critically impact the acquisition of stem-like functional properties,
and/or tumor immune resistance, and the role of each of these
pathways in such phenomena are subjects of further studies.
In this study, we observed that greater stemness, as defined by
microarray similarity, was inversely associated with brain tumor
malignancy (Fig. S1C). Careful comparison of published literature
indicates that somewhat comparable patterns have been previously
observed by others [1,2]. Specifically, limiting dilution analysis of
multiple medulloblastomas, and GBMs by the same authors [1,2]
reveal consistently lower propensity of GBM relative to medullo-
blastomas to form neurospheres enriched for tumor initiating
tumor cells, although low grade astrocytomas also generated few
neurospheres [1,2]. In contrast, we and others observed a loose
correlation between CD133 expression and glioma stemness, yet
significantly higher CD133 expression in high-grade relative to
low-grade gliomas (Fig. S1C)[1,2]. These distinct tumors all grow
in different ways, within distinct parts of the brain, which may
impact malignancy. Moreover, the cell of origin for these tumors is
hypothesized to be distinct, which may be a major factor
impacting the frequency of CSCs in each tumor type. Thus, the
relationship of CD133 expression and other metrics to stem cell
properties of brain tumors may be complex, and therefore requires
further clarification.
We observed a superior correlation between vaccine-induced,
as opposed to standard therapy-induced, and GSC gene
expression (Fig. 1B). In this context, vaccination, like chemo-
therapy, appeared to enhance stem-like properties in gliomas,
yet significantly benefited murine, and perhaps human, host
survival (Fig. 4D)[16,17,23]. Together, these observations
suggest that enrichment of stem-like gliomas might be
disassociated at least under certain physiological conditions
from greater tumor malignancy, a notion that is also consistent
with GSCs exacerbating malignancy within discrete GBM
subcategories [19]. Such disassociation was evident in vaccine-
exposed GL26 (GL26B6V) growing in nude hosts, which was
no more lethal than their counterparts (GL26, GL26nu;
Fig. 4C). In this respect, vaccine-exposed gliomas appeared
somewhat distinct from classical GSCs defined by CD133
expression and/or neurosphere selection. Since classical GSCs
are also enriched by treatments such as chemotherapy, we
would expect vaccination and chemotherapy to synergize in the
event they eliminated distinct GSC subpopulations. Neverthe-
less, the lack of synergy between vaccination and chemotherapy
in mice is consistent with chemotherapy sparing the same stem-
like tumor subset as vaccination (Fig. 4D). Together with the
apparent synergy between endogenous T cell activity and
chemotherapy, this supports a model in which endogenous anti-
tumor T cell activity and standard chemotherapy, may each
eliminate distinct individual non-stem tumor subpopulations,
whereas vaccine-induced T cell activity eliminates both. In this
manner, both vaccination and chemotherapy could enrich
stem-like tumor cells, but vaccination would do so more
efficiently. Thus, chemotherapy-exposed and vaccine-exposed
gliomas may harbor similar stem-like components, but each
may also be accompanied by distinct non-stem tumor
subpopulations, as illustrated in Fig. 7.
Our findings are most consistent with a selective rather than
inductive model of stem-like tumor enrichment by T cell
activity, which specifically predicts a delay in tumor growth
afforded by DC vaccination (Fig. 5A), as well as selective CTL
resistance of stem-like glioma cells. Both properties were
observed using the GL26 system (Fig. 4D, 5B). Nevertheless,
further studies are required to fully test whether GSCs are
enriched by DC vaccination solely via selection, as it is unclear
whether differential killing of GL26B6V at the relatively high
E:T ratios presented here is sufficient to entirely account for
vaccine-mediated promotion of stem-like properties in GL26.
Differential susceptibility to cytolytic therapeutics including
radiation and chemotherapy also enrich classical GSCs [14,15],
but the relationship between these and vaccine-elicited gliomas
requires further clarification. An additional possibility is that
decreased immunogenicity of stem-like GL26 cells contribute to
their enrichment after DC vaccination. In this context, we have
observed no quantitative or qualitative difference in dominant
antigen-directed T cell responses mediated by re-implantation
GL26B6V relative to parental GL26 into wild-type mouse
brains (5965% vs 5365% Trp-2-reactive intracranial CD8
+ T
cells, respectively; n=7 mice each for GL26 and GL26B6V;
implanted mice survived significantly longer (P,0.003) with temozolamide treatment, while GL26B6V-implanted mice did not (P.0.7). (C) Female
wild-type C57BL/6J (Jackson Labs; right panel) or nude mice (Harlan, Inc.; left panel) as indicated were injected intracranially with indicated doses of
GL26 (n=5), GL26B6 (n=5), or GL26B6V (n=5) tumor cells, and days to survival assessed by log-rank. GL26-implanted survived significantly longer
(P,0.0001; Mantel-Cox log-rank) than GL26B6V-implanted wild-type mice at doses up to 50,000 cells (not shown), but only just achieved significantly
longer survival in nude mice at doses of 25 cells (P=0.049; Mantel-Cox log-rank, not shown). (D) Survival between GL26-implanted nude (n=28),
untreated C57BL/6J (n=32), and C57BL/6J mice vaccinated with 2610
6 GL26 lysate-pulsed DC2.4 cells 3 and 7 days post-tumor implantation (n=19)
was assessed with and without subsequent temozolamide (TMZ) treatment as above, by Mantel-Cox log-rank statistics. DC-vaccinated hosts survived
significantly longer relative to untreated wild-type and nude mice implanted simultaneously with 50,000 original GL26 tumor cells (P,0.003).
doi:10.1371/journal.pone.0010974.g004
T Cells in Glioma Stemness
PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e10974P=0.23, single-side T-test; not shown). Thus, we believe CTL
resistance may play a more prominent role in enrichment of
stem-like GL26 than reduced immunogenicity.
Despite globally homogeneous gene expression in classical
GSCs, significantly higher heterogeneity within progenitor/
differentiation genes was evident in more stem-like GBM from
Figure 5. Selection vs. induction of stem-like properties in gliomas. (A) Expected appearance of gliomas under alternative mechanisms of
selection of pre-existing glioma stem cells (top panel) vs. induction of stem-like genetic program (bottom panel) via vaccination. The present data
best support the occurrence of immune-mediated glioma CSC selection with or without prior immune induction of these cells. (B) Vaccine-exposed
(GL26B6V) and parental GL26 were co-incubated with indicated ratios of HTB-156.7.7 (an H-2K
b-reactive T hybridoma [39]), and assessed for killing. A
representative of 3 independent assays is shown. GL26B6V exhibited relative resistance to killing, consistent with a selection mechanism for T cell-
mediated enrichment of stem-like gliomas. Asterisks denote significantly reduced specific lysis in triplicate wells (P.0.05 by single-sided T-test).
doi:10.1371/journal.pone.0010974.g005
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PLoS ONE | www.plosone.org 13 June 2010 | Volume 5 | Issue 6 | e10974Figure 6. Genetic diversity and stem-like properties in GBM. (A) Henry Ford Hospital GBM (‘‘GBM’’, total n=200), and cultured GBM lines
grown in stem cell media (‘‘HFH CS lines’’, total n=23) as indicated (GEO accession #GSE4536 for both), were arranged in groups with increasing
global CSC similarity as in Fig. 1B (n=20/group for GBM, groups A-J; n=5 for 4 groups, and n=3 for the most stem-like group for GBM progenitors;
groups GSC-A through -E), each with progressively increased CSC similarity, and intra-group pair-wise relatedness assessed by Pearson’s correlation
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GSCs may contribute to GBM heterogeneity by promoting
heterogeneous expression within genes involved in progenitor cell
function and/or differentiation. Similarly compartmentalized
heterogeneity was also evident in our patients’ GBM tissue prior
to DC vaccination, but was significantly decreased in GBM tissue
acquired after DC vaccination from the same patients (Fig. 6B).
The basis for why stem-like GBM tissue should be associated with
heterogeneous expression in progenitor/differentiation genes,
whereas DC vaccination that apparently increases stemness in
these tumors is associated with decreased heterogeneity is unclear,
but could reflect the persistence of distinct contaminating tumor
subpopulations co-enriched with GSCs in situ. Alternatively, the
discrepancy could reflect that classical GSCs, being enhanced by
relatively weak endogenous anti-tumor T cell activity, may differ
qualitatively from GSCs enhanced by strong vaccine-mediated T
cell activity. Further studies are needed to critically test these
possibilities. More practically, however, compartmentalized het-
erogeneity within progenitor/differentiation genes could conceiv-
ably allow tumors to evade targeted or conventional treatments via
outgrowth of resistant tumor variants, whereas homogenized gene
expression could potentially enhance susceptibility to such
therapies. In this context, the findings of progenitor/differentiation
gene homogenization after vaccination, coupled with more
heterogeneous expression of these genes under conditions of T
cell deficiency in GL26, are particularly intriguing in that they
point to a previously undocumented ability of immune activity to
constrain tumor genetic variation. Although the relationship of
heterogeneous expression within the progenitor/differentiation
gene set examined to phenotypic heterogeneity in gliomas has yet
to be established, reduced genetic variation in general could
conceivably impact adaptive tumor responses and thereby stabilize
therapeutic efficacy in GBM.
Together these findings provide the first evidence that tumor
stemness can be regulated by a targetable physiological process,
namely anti-tumor T cell activity. Moreover, they highlight that
immune resistance, like chemoresistance, may be accompanied by
greater reliance on stem cell signaling pathways. Moreover, they
provide evidence that tumor malignancy may not be directly
associated with stem-like tumor components in all cases. Further
study is required to establish the precise relationship between
vaccine-elicited gliomas and classical GSCs, and between non-
stem and stem-like tumor components, but manipulation of
physiological processes inducing glioma stemness promises con-
tinued clarification of GSC origins, treatment susceptibility, and
their role in tumor malignancy.
Supporting Information
Figure S1 Validation of GSC similarity to distinguish CSCs
from non-fractionated GBM. (A) GSC similarity (Pearson’s
coefficient for similarity to GSCs across all transcripts), and
CD133 expression, were determined for GBM from HFH
(n=200) and high-grade gliomas from UCLA (n=45; GEO
accession #GSE4412), plotted against each other for each
individual sample, trendlines generated, and r and P values
determined as depicted. CSC similarity correlated significantly
with CD133 expression within two separate databases. (B) Ability
of CD133 expression, or GSC similarity, to distinguish non-
fractionated GBM from CD133
2 or CD133
+ GSCs (29) (GEO
accession #GDS2728) or from stem cell media-cultured GBM
lines from 2 patients (37) (GEO accession #GSE4536); was
determined (P,0.01 denoted by red asterisk). Unlike CD133
expression, only GSC similarity distinguished CD133
+ or CD133
GSCs (from multiple sources) from surgical GBM samples (C)
GSC similarity (Pearson’s coefficient for similarity to GSCs - GEO
accession #GDS2728 - across all transcripts), and CD133
expression, were determined for de novo GBM, secondary
GBM, and grade 3 gliomas from UCLA (GEO accession
#GSE4412) and each parameter assessed for inter-group
differences by one-tailed T-test (P,0.01 denoted by red asterisk).
CD133 expression has been shown to be highest in de novo GBM
matrix across all transcripts, and within genes involved in differentiation/progenitor cell function (publically posted by Superarray, Inc.) as indicated.
Range and average (horizontal bar) of individual coefficients are plotted in uncolored panels, with compiled averages 6 SEM for all transcripts and
differentiation/progenitor genes combined in colored panels. Significant differences in intra-group similarity between the two gene sets are denoted
by asterisks (P,0.01; ANOVA). (B) Pre- and post-vaccine CSMC GBM (left panel; n=6 matched pairs), and mouse GL26 microarray samples recovered
from nude, syngeneic C57BL/6 (‘‘WT’’), or DC-vaccinated C57BL/6 (‘‘Vac’’; right panel; n$4/group, as described in Fig. 1A), were grouped and assessed
for intra-group pair-wise relatedness by generating Pearson’s correlation matrices across all transcripts, or for differentiation/progenitor cell genes as
above. Compiled averages 6 SEM for all transcripts (red) and differentiation/progenitor genes (green) were plotted, with significant differences
between these two parameters denoted by asterisks (P,0.01; ANOVA).
doi:10.1371/journal.pone.0010974.g006
Figure 7. Model for vaccine-induced stem-like properties in
gliomas. Model accounting for qualitatively and quantitatively distinct
enrichment of glioma CSCs by endogenous T cells, chemotherapy and
vaccination. The model takes distinct synergy of endogenous and
vaccine-mediated T cell activity with chemotherapy, and therapy-
mediated marker dynamics into account. In the absence of any T cells,
substantial numbers of Egfr
+ tumor cells are expected to persist,
whereas T cells down-regulate Egfr and proportionally up-regulate Shh
expression.
doi:10.1371/journal.pone.0010974.g007
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but global GSC similarity was highest in grade 3 gliomas and
secondary GBM (Fig. S1C). Global GSC similarity thus paralleled
increased numbers of CSCs reported for lower-grade brain tumors
(1, 2). These data validated that gene expression similarity
distinguishes stem-like gliomas more faithfully than does CD133
expression.
Found at: doi:10.1371/journal.pone.0010974.s001 (1.87 MB TIF)
FigureS2 Stem-like gene expression accompanies endogenous and
vaccine-induced anti-tumor T cell activity in gliomas. (A) Principal
Component Analyses focused on discrete gene lists were plotted in
GenespringGX7.3, and group clusters circled, on the following: 59
GBMs from UCLA database (‘‘UCLA GBM’’), 12 GBMs from 6
patients collected before and after DC vaccination (‘‘vaccinated
GBM’’);10 GBMs from 5 patients collected before and after standard
radiation and/or chemotherapy (‘‘control GBM’’) (red); CD133 and
CD133
+ CSCs from 6 University of Regensberg GBM patients (29)
(‘‘UR GSC’’) (green); stem cell media-cultured lines from 2 Henry
Ford Hospital GBM patients (‘‘HFH CS lines’’); murine GL26
glioma samples recovered and cultured ,8 passages from brains of 5
nude (GL26nu), 4 C57BL/6J (GL26B6) and 4 C57BL/6J mice
vaccinated with 107 tumor lysate-pulsed DC2.4 cells 3 and 7 d post-
tumor implantation (GL26B6V). Post-vaccine GBM uniquely
exhibited co-clustering (relatedness) with UCLA glioma progenitors
within genes involved in immune modulation (left, middle panels).
GL26B6V exhibited parallel clustering in the analogous mouse gene
list (right panel).(B) CSCsimilarity (Pearson’s coefficient for similarity
to GSCs across all transcripts) of GBM patients for whom IFN-c anti-
tumor response data was known prior to vaccine therapy was plotted
against pre-vaccine anti-tumor response levels as described (23)
revealing a significant direct correlation between CSC similarity and
response magnitude. (C) Matched microarray data from the 12
vaccinated GBM (Vaccine Rx), and the 10 control GBM (Standard
Rx) were assessed for similarity to averaged expression values of UR
GSCs (29) (‘‘UR’’), or to 20 HFH CS lines (‘‘HFH’’), and Pearson’s
coefficients across 54,674 transcripts plotted for each patient in line
plots. Significantly increased stem-like gene expression (asterisks) was
unique to post-vaccine samples (P,0.001; one-tailed T-test). See
Fig. 1 legend for GEO accession numbers.
Found at: doi:10.1371/journal.pone.0010974.s002 (1.79 MB TIF)
Figure S3 Ingenuity Pathways Analysis of vaccine-altered glioma
genes. The involvement of vaccine-altered genes in 20 pathways
containing known oncogenes is scored by a ratio of the number of
vaccine-altered genes to the number of genes in each pathway. (A)
Human GBM post-vaccine up-regulation. (B) Murine GL26 post-
vaccine up-regulation. (C) Human GBM post-vaccine down-
regulation. (D) Murine GL26 post-vaccine down-regulation. Up
and down regulated genes were scored separately. Shown here are
the 11 pathways with the highest ratios of changed genes to total
genes among 20 pathways of interest. Signaling Pathways:
Apoptosis, Death Receptor, EGF, ERK/MAPK, Estrogen Recep-
tor, GF-1, NF-kappaB, Notch, p38 MAPK, PDGF, PI3K/AKT,
PTEN, Sonic Hedgehog, TGF-beta2, VEGF, Wnt/beta-catenin;
Other pathways: Cell Cycle: G1/S Checkpoint Regulation, Cell
Cycle: G2/M DNA, Damage Checkpoint Regulation, Nucleotide
Excision Repair Pathway, Protein Ubiquitination Pathway.
Found at: doi:10.1371/journal.pone.0010974.s003 (1.87 MB TIF)
Figure S4 Progressive chemo-resistance and tumorigenicity in
GL26. (A) Cell numbers + indicated concentrations of temozola-
mide were determined for low-passage (,5) GL26nu, GL26B6 and
GL26B6V using a Coulter counter, and demonstrates progressive
chemo-resistance related to anti-tumor T cell response strength. (B)
Female nude mice (Harlan, Inc.; right panel) as indicated were each
injected intracranially with 100 GL26 (n=5), GL26B6 (n=5), or
GL26B6V (n=5) tumor cells, and days to survival assessed by log-
rank statistics. GL26-implanted mice survived marginally but
significantly longer than GL26B6V-implanted mice only at doses
of 25 cells (P=0.049; not shown). (C, D) Fifty-thousand GL26B6-
GFP or parental GL26 cells were implanted into female hosts, with
significantly longer survival of GL26B6-GFP-bearing nudes (Har-
lan, Inc.) and significantly shorter survival of GL26B6-GFP-bearing
WT C57Bl/6 (Jackson Labs; black) confirmed relative to GL26-
bearing females prior to further analysis (P=0.004 and P=0.029,
respectively). Fifty-thousand total tumor cells were then implanted
into nude or WT brains at the indicated ratios of admixed GL26B6-
GFP (GFP+) to parental GL26 cells, and brains from terminally
symptomatic mice either sectioned for serial H&E/immunofluores-
cence analysis (C, right and left panels, respectively), or tumors
excised, recovered by adherence to tissue culture plastic, and
numbers oftotal and GFP+ tumorcellscountedseparately (n=2 for
C57BL/6; n=3 for nude mice). Average proportions of GFP+
tumor cells + standard error are depicted in (D). GFP+ and GFP-
tumors were present in all mice (C), in expected proportions at 4:1
GL26B6-GFP:GL26 in nude or WT (2- to 8-fold GFP+; P=0.222
between nude and WT, 2-sided T test), with GL26B6-GFP
overrepresentation at 1:4 in WT relative to nude (1.9 vs., 0.7-fold
GFP+; P=0.00032, 2-sided T test).
Found at: doi:10.1371/journal.pone.0010974.s004 (1.96 MB TIF)
Table S1 Probesets for human GBM analysis. Entire lists of
1581 vaccine-altered, 202 EGFR- and SHH-related, 163 cyto-
kine/immune modulator, and 944 progenitor cell/differentiation
probesets (HG133+2 chip) used in microarray analyses in
Figures 1, 6, S1, S2, S3, S4, and S6, can be found in Table S1.
Found at: doi:10.1371/journal.pone.0010974.s005 (0.13 MB
XLS)
Table S2 Probesets for mouse GL26 analysis. Entire lists of 1293
vaccine-altered, 158 EGFR- and SHH-related, 136 cytokine/
immune modulator, and 763 progenitor cell/differentiation
probesets (MG480+2 chip) used in microarray analyses in
Figures 1, 6, S1, S2, S3, S4, and S6, can be found in Table S2.
Found at: doi:10.1371/journal.pone.0010974.s006 (0.11 MB
XLS)
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